Do analysts prefer AKTX or SNGX?

Akari Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 219.50%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, AKTX or SNGX?

Soligenix has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Soligenix $120K 44.46 -$11.08M -$0.98 N/A

Is AKTX or SNGX more profitable?

Akari Therapeutics' return on equity of -147.45% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -147.45% -74.70% Soligenix N/A -180.25% -107.46%

Do analysts prefer LGVN or SNGX?

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 1,097.60%. Given Longeveron's stronger consensus rating and higher possible upside, research analysts clearly believe Longeveron is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LGVN or SNGX more profitable?

Soligenix has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Soligenix's return on equity of -180.25% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,977.59% -223.19% -150.20% Soligenix N/A -180.25% -107.46%

Do analysts rate QNTM or SNGX?

Quantum Biopharma presently has a consensus target price of $8.00, indicating a potential upside of 119.18%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Quantum Biopharma is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QNTM or SNGX more profitable?

Soligenix's return on equity of -180.25% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Soligenix N/A -180.25% -107.46%

Do analysts recommend SNGX or NEUP?

Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 87.17%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SNGX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Neuphoria Therapeutics N/A -76.93% -54.76%

Soligenix (SNGX) Competitors

$0.36 0.00 (-0.03%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.36 +0.00 (+0.28%)

As of 08:40 AM Eastern

Compare

SNGX vs. AKTX, MRKR, LGVN, QNTM, and NEUP

Should you buy Soligenix stock or one of its competitors? Soligenix's main competitors and comparable companies include Akari Therapeutics (AKTX), Marker Therapeutics (MRKR), Longeveron (LGVN), Quantum Biopharma (QNTM), and Neuphoria Therapeutics (NEUP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Soligenix compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 1.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Akari Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Akari Therapeutics and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.89 beat Akari Therapeutics' score of 1.28 indicating that Soligenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Akari Therapeutics	Positive
Soligenix	Very Positive

Akari Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 219.50%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Soligenix has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Soligenix	$120K	44.46	-$11.08M	-$0.98	N/A

Akari Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Akari Therapeutics' return on equity of -147.45% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
Soligenix	N/A	-180.25%	-107.46%

Summary

Akari Therapeutics beats Soligenix on 8 of the 12 factors compared between the two stocks.

How does Soligenix compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Soligenix has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	5.35	-$12.16M	-$0.41	N/A
Soligenix	$120K	44.46	-$11.08M	-$0.98	N/A

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 777.19%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Marker Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Soligenix has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -56.96% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
Soligenix	N/A	-180.25%	-107.46%

Marker Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Soligenix's average media sentiment score of 1.89 beat Marker Therapeutics' score of 1.87 indicating that Soligenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Marker Therapeutics	Very Positive
Soligenix	Very Positive

Summary

Marker Therapeutics beats Soligenix on 9 of the 15 factors compared between the two stocks.

How does Soligenix compare to Longeveron?

Longeveron (NASDAQ:LGVN) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Soligenix has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Soligenix's return on equity of -180.25% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Soligenix	N/A	-180.25%	-107.46%

In the previous week, Longeveron had 8 more articles in the media than Soligenix. MarketBeat recorded 9 mentions for Longeveron and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.89 beat Longeveron's score of 0.40 indicating that Soligenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Longeveron	Neutral
Soligenix	Very Positive

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 7.4% of Longeveron shares are owned by insiders. Comparatively, 1.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 1,097.60%. Given Longeveron's stronger consensus rating and higher possible upside, research analysts clearly believe Longeveron is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Longeveron has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Soligenix has lower revenue, but higher earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	17.76	-$22.70M	-$9.90	N/A
Soligenix	$120K	44.46	-$11.08M	-$0.98	N/A

Summary

Soligenix beats Longeveron on 9 of the 16 factors compared between the two stocks.

How does Soligenix compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Quantum Biopharma presently has a consensus target price of $8.00, indicating a potential upside of 119.18%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Quantum Biopharma is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Soligenix's return on equity of -180.25% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Soligenix	N/A	-180.25%	-107.46%

In the previous week, Quantum Biopharma had 6 more articles in the media than Soligenix. MarketBeat recorded 7 mentions for Quantum Biopharma and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.89 beat Quantum Biopharma's score of 0.44 indicating that Soligenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Soligenix	Very Positive

Soligenix has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Soligenix	$120K	44.46	-$11.08M	-$0.98	N/A

Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Soligenix beats Quantum Biopharma on 9 of the 14 factors compared between the two stocks.

How does Soligenix compare to Neuphoria Therapeutics?

Soligenix (NASDAQ:SNGX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

3.6% of Soligenix shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.9% of Soligenix shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	44.46	-$11.08M	-$0.98	N/A
Neuphoria Therapeutics	$15.65M	1.29	-$370K	-$11.06	N/A

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.89 beat Neuphoria Therapeutics' score of 0.93 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Very Positive
Neuphoria Therapeutics	Positive

Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 87.17%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Soligenix has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Summary

Neuphoria Therapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.34M	$3.84B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-0.37	14.33	273.84	25.33
Price / Sales	44.46	1,393.75	638.10	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	0.69	15.13	10.32	6.24
Net Income	-$11.08M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-0.03%	-2.54%	-0.84%	-1.20%
1 Month Performance	-5.56%	-2.87%	-1.37%	-4.26%
1 Year Performance	-87.19%	37.92%	21.12%	5.47%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	0.8402 of 5 stars	$0.36 0.0%	N/A	-87.1%	$5.34M	$120K	N/A	20	Positive News
AKTX Akari Therapeutics	3.3246 of 5 stars	$10.96 -4.4%	$32.33 +195.0%	-66.5%	$21.37M	N/A	N/A	9	News Coverage Positive News Gap Up
MRKR Marker Therapeutics	3.0684 of 5 stars	$1.28 +8.5%	$10.00 +681.3%	+14.6%	$21.34M	N/A	N/A	60
LGVN Longeveron	2.5436 of 5 stars	$6.65 -2.3%	$80.00 +1,103.0%	-10.9%	$21.20M	$1.19M	N/A	20	News Coverage
QNTM Quantum Biopharma	2.6162 of 5 stars	$3.29 +1.5%	$8.00 +143.2%	-78.1%	$21.06M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. AKTX, MRKR, LGVN, QNTM, and NEUP

How does Soligenix compare to Akari Therapeutics?

Summary

How does Soligenix compare to Marker Therapeutics?

Summary

How does Soligenix compare to Longeveron?

Summary

How does Soligenix compare to Quantum Biopharma?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. AKTX, MRKR, LGVN, QNTM, and NEUP

How does Soligenix compare to Akari Therapeutics?

Do insiders & institutionals believe in AKTX or SNGX?

Does the media favor AKTX or SNGX?

Do analysts prefer AKTX or SNGX?

Which has higher earnings and valuation, AKTX or SNGX?

Which has more risk & volatility, AKTX or SNGX?

Is AKTX or SNGX more profitable?

Summary

How does Soligenix compare to Marker Therapeutics?

Which has stronger valuation and earnings, MRKR or SNGX?

Do analysts prefer MRKR or SNGX?

Is MRKR or SNGX more profitable?

Which has more volatility & risk, MRKR or SNGX?

Do insiders and institutionals believe in MRKR or SNGX?

Does the media favor MRKR or SNGX?

Summary

How does Soligenix compare to Longeveron?

Is LGVN or SNGX more profitable?

Does the media favor LGVN or SNGX?

Do institutionals & insiders believe in LGVN or SNGX?

Do analysts prefer LGVN or SNGX?

Which has more volatility and risk, LGVN or SNGX?

Which has better earnings & valuation, LGVN or SNGX?

Summary

How does Soligenix compare to Quantum Biopharma?

Do analysts rate QNTM or SNGX?

Is QNTM or SNGX more profitable?

Does the media favor QNTM or SNGX?

Which has higher earnings and valuation, QNTM or SNGX?

Which has more risk & volatility, QNTM or SNGX?

Do institutionals and insiders believe in QNTM or SNGX?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Is SNGX or NEUP more profitable?

Do insiders and institutionals have more ownership in SNGX or NEUP?

Which has stronger valuation & earnings, SNGX or NEUP?

Does the media refer more to SNGX or NEUP?

Do analysts recommend SNGX or NEUP?

Which has more volatility and risk, SNGX or NEUP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools